Paracrine co-delivery of TGF-β and IL-2 using CD4-targeted nanoparticles for induction and maintenance of regulatory T cells

Biomaterials

Volumn 59, Issue , 2015, Pages 172-181

  McHugh, Michael D ^a   Park, Jason ^a   Uhrich, Ross ^a   Gao, Wenda ^b   Horwitz, David A ^c   Fahmy, Tarek M ^a,d  

^a Yale University   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Autoimmunity; Drug delivery; Immunomodulation; Interleukin 2; Nanoparticles; TGF

Indexed keywords

BIOCHEMISTRY; CONTROLLED DRUG DELIVERY; CYTOLOGY; DRUG DELIVERY; NANOPARTICLES; PATHOLOGY; TARGETED DRUG DELIVERY;

AUTOIMMUNITY; BIODEGRADABLE NANOPARTICLE; IMMUNO MODULATIONS; INTERLEUKIN-2; PLEIOTROPIC EFFECTS; PRO-INFLAMMATORY CYTOKINES; TARGETED NANOPARTICLE; TRANSFORMING GROWTH FACTOR BETA;

T-CELLS;

CD4 ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 2; NANOPARTICLE; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ARTICLE; BIOAVAILABILITY; CD4+ T LYMPHOCYTE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG DELIVERY SYSTEM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; IMMUNOMODULATION; IN VITRO STUDY; MOUSE; NONHUMAN; PARACRINE SIGNALING; PHENOTYPE; PLEIOTROPY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REGULATORY T LYMPHOCYTE; SCANNING ELECTRON MICROSCOPY; SPLEEN CELL; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CELL LINE; IMMUNOLOGY;

ERAGROSTIS TEF;

ANIMALS; ANTIGENS, CD4; CELL LINE; FEMALE; INTERLEUKIN-2; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NANOPARTICLES; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA;

EID: 84930162556     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2015.04.003     Document Type: Article

References (58)

1. Sakaguchi S., Yamaguchi T., Nomura T., Ono M. Regulatory T cells and immune tolerance. Cell 2008, 133(5):775-787.
2. Chaudhry A., Rudensky A.Y. Control of inflammation by integration of environmental cues by regulatory T cells. JClin Invest 2013, 123(3):939-944.
3. Maloy K.J., Powrie F. Regulatory T cells in the control of immune pathology. Nat Immunol 2001, 2(9):816-822.
4. Wildin R.S., Ramsdell F., Peake J., Faravelli F., Casanova J.L., Buist N., et al. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet 2001, 27(1):18-20.
5. Roep B.O., Peakman M. Antigen targets of type 1 diabetes autoimmunity. Cold Spring Harb Perspect Med 2012, 2(4). a007781.
6. Jager A., Dardalhon V., Sobel R.A., Bettelli E., Kuchroo V.K. Th1, Th17, and Th9 effector cells induce experimental autoimmune encephalomyelitis with different pathological phenotypes. JImmunol 2009, 183(11):7169-7177.
7. Cao D., Malmstrom V., Baecher-Allan C., Hafler D., Klareskog L., Trollmo C. Isolation and functional characterization of regulatory CD25brightCD4+ T cells from the target organ of patients with rheumatoid arthritis. Eur J Immunol 2003, 33(1):215-223.
8. Viglietta V., Baecher-Allan C., Weiner H.L., Hafler D.A. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. JExp Med 2004, 199(7):971-979.
9. Sugiyama H., Gyulai R., Toichi E., Garaczi E., Shimada S., Stevens S.R., et al. Dysfunctional blood and target tissue CD4+CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation. JImmunol 2005, 174(1):164-173.
10. Lindley S., Dayan C.M., Bishop A., Roep B.O., Peakman M., Tree T.I. Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes. Diabetes 2005, 54(1):92-99.
11. Balandina A., Saoudi A., Dartevelle P., Berrih-Aknin S. Analysis of CD4+CD25+ cell population in the thymus from myasthenia gravis patients. Ann N Y Acad Sci 2003, 998:275-277.
12. Zhou X., Kong N., Zou H., Brand D., Li X., Liu Z., et al. Therapeutic potential of TGF-beta-induced CD4(+) Foxp3(+) regulatory T cells in autoimmune diseases. Autoimmunity 2011, 44(1):43-50.
13. Abbas A.K., Benoist C., Bluestone J.A., Campbell D.J., Ghosh S., Hori S., et al. Regulatory T cells: recommendations to simplify the nomenclature. Nat Immunol 2013, 14(4):307-308.
14. Sakaguchi S., Sakaguchi N., Shimizu J., Yamazaki S., Sakihama T., Itoh M., et al. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 2001, 182:18-32.
15. Floess S., Freyer J., Siewert C., Baron U., Olek S., Polansky J., et al. Epigenetic control of the foxp3 locus in regulatory T cells. PLoS Biol 2007, 5(2):e38.
16. Chen Y., Kuchroo V.K., Inobe J., Hafler D.A., Weiner H.L. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 1994, 265(5176):1237-1240.
17. Nakamura K., Kitani A., Strober W. Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. JExp Med 2001, 194(5):629-644.
18. Kingsley C.I., Karim M., Bushell A.R., Wood K.J. CD25+CD4+ regulatory T cells prevent graft rejection: CTLA-4- and IL-10-dependent immunoregulation of alloresponses. JImmunol 2002, 168(3):1080-1086.
19. Lu L., Wang J., Zhang F., Chai Y., Brand D., Wang X., et al. Role of SMAD and non-SMAD signals in the development of Th17 and regulatory T cells. JImmunol 2010, 184(8):4295-4306.
20. Zheng S.G., Wang J., Horwitz D.A. Cutting edge: foxp3+CD4+CD25+ regulatory T cells induced by IL-2 and TGF-beta are resistant to Th17 conversion by IL-6. JImmunol 2008, 180(11):7112-7116.
21. Kong N., Lan Q., Chen M., Wang J., Shi W., Horwitz D.A., et al. Antigen-specific transforming growth factor beta-induced Treg cells, but not natural Treg cells, ameliorate autoimmune arthritis in mice by shifting the Th17/Treg cell balance from Th17 predominance to Treg cell predominance. Arthritis Rheum 2012, 64(8):2548-2558.
22. Kasagi S., Zhang P., Che L., Abbatiello B., Maruyama T., Nakatsukasa H., et al. Invivo-generated antigen-specific regulatory T cells treat autoimmunity without compromising antibacterial immune response. Sci Transl Med 2014, 6(241). 241ra78.
23. Fontenot J.D., Rasmussen J.P., Gavin M.A., Rudensky A.Y. Afunction for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol 2005, 6(11):1142-1151.
24. Li M.O., Wan Y.Y., Flavell R.A. Tcell-produced transforming growth factor-beta1 controls T cell tolerance and regulates Th1- and Th17-cell differentiation. Immunity 2007, 26(5):579-591.
25. Fahmy T.M., Schneck J.P., Saltzman W.M. Ananoscopic multivalent antigen-presenting carrier for sensitive detection and drug delivery to T cells. Nanomed Nanotechnol Biol Med 2007, 3(1):75-85.
26. Park J., Gao W., Whiston R., Strom T.B., Metcalfe S., Fahmy T.M. Modulation of CD4+ T lymphocyte lineage outcomes with targeted, nanoparticle-mediated cytokine delivery. Mol Pharm 2011, 8(1):143-152.
27. Stephan M.T., Moon J.J., Um S.H., Bershteyn A., Irvine D.J. Therapeutic cell engineering with surface-conjugated synthetic nanoparticles. Nat Med 2010, 16(9):1035-1041.
28. Mundargi R.C., Babu V.R., Rangaswamy V., Patel P., Aminabhavi T.M. Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives. JControl Release: Off J Control Release Soc 2008, 125(3):193-209.
29. Demento S.L., Cui W., Criscione J.M., Stern E., Tulipan J., Kaech S.M., et al. Role of sustained antigen release from nanoparticle vaccines in shaping the T cell memory phenotype. Biomaterials 2012, 33(19):4957-4964.
30. Jhunjhunwala S., Balmert S.C., Raimondi G., Dons E., Nichols E.E., Thomson A.W., et al. Controlled release formulations of IL-2, TGF-beta1 and rapamycin for the induction of regulatory T cells. JControl Release: Off J Control Release Soc 2012, 159(1):78-84.
31. Mahapatro A., Singh D.K. Biodegradable nanoparticles are excellent vehicle for site directed in-vivo delivery of drugs and vaccines. JNanobiotechnol 2011, 9:55.
32. Steenblock E.R., Fadel T., Labowsky M., Pober J.S., Fahmy T.M. An artificial antigen-presenting cell with paracrine delivery of IL-2 impacts the magnitude and direction of the T cell response. JBiol Chem 2011, 286(40):34883-34892.
33. Steenblock E.R., Fahmy T.M. Acomprehensive platform for exvivo T-cell expansion based on biodegradable polymeric artificial antigen-presenting cells. Mol Ther: J Am Soc Gene Ther 2008, 16(4):765-772.
34. Keegan M.E., Royce S.M., Fahmy T., Saltzman W.M. Invitro evaluation of biodegradable microspheres with surface-bound ligands. JControl Release: Off J Control Release Soc 2006, 110(3):574-580.
35. Park J., Mattessich T., Jay S.M., Agawu A., Saltzman W.M., Fahmy T.M. Enhancement of surface ligand display on PLGA nanoparticles with amphiphilic ligand conjugates. JControl Release: Off J Control Release Soc 2011, 156(1):109-115.
36. Fahmy T.M., Samstein R.M., Harness C.C., Mark Saltzman W. Surface modification of biodegradable polyesters with fatty acid conjugates for improved drug targeting. Biomaterials 2005, 26(28):5727-5736.
37. Bettelli E., Carrier Y., Gao W., Korn T., Strom T.B., Oukka M., et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441(7090):235-238.
38. Roederer M. Interpretation of cellular proliferation data: avoid the panglossian. Cytometry Part A: J Int Soc Anal Cytol 2011, 79(2):95-101.
39. Brunstein C.G., Miller J.S., Cao Q., McKenna D.H., Hippen K.L., Curtsinger J., et al. Infusion of exvivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood 2011, 117(3):1061-1070.
40. Marek-Trzonkowska N., Mysliwiec M., Dobyszuk A., Grabowska M., Derkowska I., Juscinska J., et al. Therapy of type 1 diabetes with CD4(+)CD25(high)CD127-regulatory T cells prolongs survival of pancreatic islets - results of one year follow-up. Clin Immunol 2014, 153(1):23-30.
41. Riley J.L., June C.H., Blazar B.R. Human T regulatory cell therapy: take a billion or so and call me in the morning. Immunity 2009, 30(5):656-665.
42. Grinberg-Bleyer Y., Baeyens A., You S., Elhage R., Fourcade G., Gregoire S., et al. IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. JExp Med 2010, 207(9):1871-1878.
43. Koreth J., Matsuoka K., Kim H.T., McDonough S.M., Bindra B., Alyea E.P., et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. NEngl J Med 2011, 365(22):2055-2066.
44. Saadoun D., Rosenzwajg M., Joly F., Six A., Carrat F., Thibault V., et al. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. NEngl J Med 2011, 365(22):2067-2077.
45. Long S.A., Buckner J.H., Greenbaum C.J. IL-2 therapy in type 1 diabetes: "Trials" tribulations. Clin Immunol 2013, 149(3):324-331.
46. Fantini M.C., Becker C., Tubbe I., Nikolaev A., Lehr H.A., Galle P., et al. Transforming growth factor beta induced FoxP3+ regulatory T cells suppress Th1 mediated experimental colitis. Gut 2006, 55(5):671-680.
47. Chen W., Jin W., Hardegen N., Lei K.J., Li L., Marinos N., et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. JExp Med 2003, 198(12):1875-1886.
48. Fantini M.C., Dominitzki S., Rizzo A., Neurath M.F., Becker C. Invitro generation of CD4+ CD25+ regulatory cells from murine naive T cells. Nat Protoc 2007, 2(7):1789-1794.
49. Labowsky M., Fahmy T.M. Diffusive transfer between two intensely interacting cells with limited surface kinetics. Chem Eng Sci 2012, 74:114-123.
50. Wrana J.L., Attisano L., Wieser R., Ventura F., Massague J. Mechanism of activation of the TGF-beta receptor. Nature 1994, 370(6488):341-347.
51. Moustakas A., Lin H.Y., Henis Y.I., Plamondon J., O'Connor-McCourt M.D., Lodish H.F. The transforming growth factor beta receptors types I, II, and III form hetero-oligomeric complexes in the presence of ligand. JBiol Chem 1993, 268(30):22215-22218.
52. Letourneur O., Goetschy J.F., Horisberger M., Grutter M.G. Ligand-induced dimerization of the extracellular domain of the TGF-beta receptor type II. Biochem Biophys Res Commun 1996, 224(3):709-716.
53. Komatsu N., Mariotti-Ferrandiz M.E., Wang Y., Malissen B., Waldmann H., Hori S. Heterogeneity of natural Foxp3+ T cells: a committed regulatory T-cell lineage and an uncommitted minor population retaining plasticity. Proc Natl Acad Sci U S A 2009, 106(6):1903-1908.
54. Zhou X., Bailey-Bucktrout S.L., Jeker L.T., Penaranda C., Martinez-Llordella M., Ashby M., et al. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells invivo. Nat Immunol 2009, 10(9):1000-1007.
55. Maincent P., Thouvenot P., Amicabile C., Hoffman M., Kreuter J., Couvreur P., et al. Lymphatic targeting of polymeric nanoparticles after intraperitoneal administration in rats. Pharm Res 1992, 9(12):1534-1539.
56. Shirali A.C., Look M., Du W., Kassis E., Stout-Delgado H.W., Fahmy T.M., et al. Nanoparticle delivery of mycophenolic acid upregulates PD-L1 on dendritic cells to prolong murine allograft survival. Am J Transpl: Off J Am Soc Transpl Am Soc Transpl Surg 2011, 11(12):2582-2592.
57. Look M., Stern E., Wang Q.A., DiPlacido L.D., Kashgarian M., Craft J., et al. Nanogel-based delivery of mycophenolic acid ameliorates systemic lupus erythematosus in mice. JClin Invest 2013, 123(4):1741-1749.
58. Maldonado R.A., LaMothe R.A., Ferrari J.D., Zhang A.H., Rossi R.J., Kolte P.N., et al. Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance. Proc Natl Acad Sci U S A 2015, 112(2):E156-E165.